partial AUCs for locally acting MR [Design Issues]

posted by jag009  – NJ, 2020-12-05 09:01 (727 d 14:34 ago) – Posting: # 22116
Views: 1,963

Hi,

❝ I’m involved in the development of a MR generic drug that is locally acting in the GI tract. Despite the very helpful new EMA guideline (Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract, CPMP/EWP/239/95 Rev. 1, Corr.1*) I´m struggling with designing the BE studies to support submission in EU.


❝ Most problematic is the justification of the cut-off for the required partial AUCs.


Something like this in US for mesalamine ER?

https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022301.pdf

J

Complete thread:

UA Flag
Activity
 Admin contact
22,424 posts in 4,694 threads, 1,600 registered users;
11 visitors (1 registered, 10 guests [including 6 identified bots]).
Forum time: 23:36 CET (Europe/Vienna)

The rise of biometry in this 20th century,
like that of geometry in the 3rd century before Christ,
seems to mark out one of the great ages or critical periods
in the advance of the human understanding.    R.A. Fisher

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5